Read + Share
Amedeo Smart
Independent Medical Education
Hurteau J, Grayeski M, Dixon J. BEHOLD phase 3 clinical development program of mocertatug rezetecan in ovarian and endometrial cancer. Gynecol Oncol 2026;215:164-167.PMID: 43013925
Email
LinkedIn
Privacy Policy